Expression of a binding structure for sialic acid-containing glycoconjugates on rat bone marrow-derived macrophages and its modulation by IFN, TNF-alpha, and dexamethasone.
Rat macrophages express a binding structure for sialic acid-containing glycoconjugates (sialic acid-binding receptor, SAR) which can be detected by a rosette assay utilizing SRBC coated with bovine brain gangliosides (E-G). Freshly isolated rat bone marrow cells (BMC) contain about 5% SAR-positive cells. Rat BMC cultured for 1 wk with tissue culture media containing CSF-1 differentiate into a virtually pure population of bone marrow-derived macrophages (BMDM phi). All BMDM phi bound E-G coated with an optimal concentration of gangliosides (100 micrograms/ml). When BMC were cultured for 1 wk with murine recombinant granulocyte-macrophage CSF, irrespective of the dose of GM-CSF, approximately 90% of the cells were identified as rat macrophages, and practically all expressed SAR. Only about 50% of BMDM phi bound SRBC coated with a suboptimal concentration of gangliosides (20 micrograms/ml). However, this percentage increased markedly after 8 to 72 h incubation with 1 to 10,000 U/ml purified murine IFN-alpha or IFN-beta, whereas murine or rat rIFN-gamma at doses above 10 U/ml led to a decrease of E-G binding. Human and murine rTNF-alpha enhanced rosette formation in a dose-dependent manner. These effects could be blocked by the respective anti-cytokine antibodies. Treatment of BMDM phi with dexamethasone also augmented E-G rosetting. The enhancement of E-G binding was abolished by pretreatment of BMDM phi with cycloheximide and actinomycin D but not with mitomycin C, suggesting that de novo synthesis of protein and RNA, but not DNA, is required. Our results demonstrate that all rat BMDM phi constitutively bear SAR, and that murine IFN-alpha, IFN-beta, and TNF-alpha, as well as dexamethasone, may augment SAR expression.
Gessl
A
A
Institute of General and Experimental Pathology, University of Vienna, Austria.
Boltz-Nitulescu
G
G
Wiltschke
C
C
Holzinger
C
C
Nemet
H
H
Pernerstorfer
T
T
Förster
O
O
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D003907:Dexamethasone / Q000494:pharmacology*; D006017:Glycolipids / Q000378:metabolism*; D006131:Growth Inhibitors / Q000494:pharmacology; D007370:Interferon Type I / Q000037:antagonists & inhibitors / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology; D007372:Interferons / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008264:Macrophages / Q000378:metabolism*; D008297:Male; D051379:Mice; D019158:N-Acetylneuraminic Acid; D051381:Rats; D011917:Rats, Inbred Lew; D011956:Receptors, Cell Surface; D011971:Receptors, Immunologic / Q000032:analysis* / Q000187:drug effects; D012794:Sialic Acids / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D006017:Glycolipids; D006131:Growth Inhibitors; D007370:Interferon Type I; D011956:Receptors, Cell Surface; D011971:Receptors, Immunologic; D012794:Sialic Acids; D014409:Tumor Necrosis Factor-alpha; C033639:glycolipid receptor; D003907:Dexamethasone; D007371:Interferon-gamma; D007372:Interferons; D019158:N-Acetylneuraminic Acid